TG Therapeutics Inc TGTX
News
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases
AMD, Kraft Heinz stocks surge, WeWork and CVS shares sink and other stocks on the move
TG Therapeutics' stock rockets after blowout earnings